Srishti Shrestha1, Pamela L Lutsey2, Alvaro Alonso2, Xuemei Huang3, Thomas H Mosley4, Honglei Chen1. 1. Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA. 2. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. 3. Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA. 4. Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, Mississippi, USA.
Abstract
BACKGROUND: Low vitamin D levels are common among patients with Parkinson's disease (PD). Experimental evidence further suggests that vitamin D may be protective against PD. The objective of this study was to prospectively assess the association between serum 25-hydroxyvitamin D and PD among 12,762 participants of the Atherosclerosis Risk in Communities Study cohort. METHODS: Serum samples were collected in 1990-1992, and 25-hydroxyvitamin D was measured by liquid chromatography mass spectrometry. A total of 67 incident PD cases were identified through December 31, 2008. The median length of follow-up was 17 years. We used Cox proportional hazards models to obtain hazard ratios and 95% confidence intervals, adjusting for age, sex, and race. We did not find any association between serum 25-hydroxyvitamin D concentrations and PD risk, regardless of how serum 25-hydroxyvitamin D was modeled. Compared with participants with serum 25-hydroxyvitamin D < 20 ng/mL, the hazards ratio for PD was 1.05 (95% confidence interval, 0.58-1.90) for 20-30 ng/mL and 1.14 (95% confidence interval, 0.59- 2.23) for ≥30 ng/mL. Similar results were obtained in sensitivity analyses that included white participants only and that were stratified by the length of follow-up. CONCLUSION: This prospective study lends no support to the hypothesis that vitamin D may reduce the risk of PD.
BACKGROUND: Low vitamin D levels are common among patients with Parkinson's disease (PD). Experimental evidence further suggests that vitamin D may be protective against PD. The objective of this study was to prospectively assess the association between serum 25-hydroxyvitamin D and PD among 12,762 participants of the Atherosclerosis Risk in Communities Study cohort. METHODS: Serum samples were collected in 1990-1992, and 25-hydroxyvitamin D was measured by liquid chromatography mass spectrometry. A total of 67 incident PD cases were identified through December 31, 2008. The median length of follow-up was 17 years. We used Cox proportional hazards models to obtain hazard ratios and 95% confidence intervals, adjusting for age, sex, and race. We did not find any association between serum 25-hydroxyvitamin D concentrations and PD risk, regardless of how serum 25-hydroxyvitamin D was modeled. Compared with participants with serum 25-hydroxyvitamin D < 20 ng/mL, the hazards ratio for PD was 1.05 (95% confidence interval, 0.58-1.90) for 20-30 ng/mL and 1.14 (95% confidence interval, 0.59- 2.23) for ≥30 ng/mL. Similar results were obtained in sensitivity analyses that included white participants only and that were stratified by the length of follow-up. CONCLUSION: This prospective study lends no support to the hypothesis that vitamin D may reduce the risk of PD.
Authors: Liyong Wang; Marian L Evatt; Lizmarie G Maldonado; William R Perry; James C Ritchie; Gary W Beecham; Eden R Martin; Jonathan L Haines; Margaret A Pericak-Vance; Jeffery M Vance; William K Scott Journal: Mov Disord Date: 2014-12-27 Impact factor: 10.338
Authors: Michelle E Fullard; Sharon X Xie; Ken Marek; Matthew Stern; Danna Jennings; Andrew Siderowf; Allison W Willis; Alice S Chen-Plotkin Journal: Mov Disord Date: 2017-09-14 Impact factor: 10.338
Authors: Ludmila A R Lima; Maria Janice P Lopes; Roberta O Costa; Francisco Arnaldo V Lima; Kelly Rose T Neves; Iana B F Calou; Geanne M Andrade; Glauce S B Viana Journal: J Neuroinflammation Date: 2018-08-31 Impact factor: 8.322